Casdin Private Growth Equity Fund, L.P. 4
4 · Verve Therapeutics, Inc. · Filed Jun 22, 2021
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2021-06-21+620,571→ 620,571 total - Conversion
Series B Preferred Stock
2021-06-21−5,746,183→ 0 total→ Common Stock (620,571 underlying)
Footnotes (2)
- [F1]The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
- [F2]The shares reflected as beneficially owned by Casdin Private Growth Equity Fund, L.P. are owned directly by Casdin Private Growth Equity Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Private Growth Equity Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein.